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Comparative assessment of Graves’ 
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Dong Yeob Shin2,5, Jin Sook Yoon6, Do Yup Lee1 & Eun Jig Lee2,5
Graves’ disease (GD) is an autoimmune disorder that causes the overproduction of thyroid hormones 
and consequent cascade of systemic metabolism dysfunction. Moreover, Graves’ ophthalmopathy 
(GO) is the main extrathyroidal manifestation of Graves’ disease (GD). The goal of the study was 
to identify metabolic signatures in association with diagnostic biomarkers of GD without GO and 
GO, respectively. Ninety metabolites were profiled and analyzed based on a non-targeted primary 
metabolite profiling from plasma samples of 21 GD patients without GO, 26 subjects with GO, and 32 
healthy subjects. Multivariate statistics showed a clear discrimination between healthy controls and 
disease group (R2Y = 0.518, Q2 = 0.478) and suggested a biomarker panel consisting of 10 metabolites. 
Among them, most of metabolites showed the positive association with the levels of thyrotropin 
receptor antibodies. With combination of proline and 1,5-anhydroglucitol, which were identified as 
GO-specific modulators, the re-constructed biomarker model greatly improved the statistical power 
and also facilitated simultaneous discrimination among healthy control, GO, and GD without GO groups 
(AUC = 0.845–0.935). Finally, the comparative analysis of tissue metabolite profiles from GO patients 
proposed putative metabolic linkage between orbital adipose/connective tissues and the biofluidic 
consequences, in which fumarate, proline, phenylalanine, and glycerol were coordinately altered with 
the blood metabolites.
Graves’ disease is the most common cause of hyperthyroidism, which results from the stimulation of autoanti-
bodies to the thyrotropin receptor of thyroid follicular cells1. It usually occurs between 30 and 50 years of age, 
but all ages can be affected2,3. Similar to other autoimmune diseases, Graves’ disease occurs more frequently in 
women than in men, with a ratio of about 5/14. Graves’ ophthalmopathy is clinically presented by about 25%-
50% of patients with Graves’ disease5. Subclinical ophthalmopathy in orbital imaging is reported in nearly 70% 
of patients with Graves’ disease6 and severe ophthalmopathy affects 3%–5% of patients, with sight-threatening 
complications, such as corneal breakdown or compressive optic neuritis7.
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Graves’ disease can be diagnosed with clinical signs and symptoms of hyperthyroidism, thyroid function 
tests, and positivity of thyrotropin (thyroid stimulating hormone, TSH) receptor antibodies (TRAb). Although 
TRAb assays have relatively high sensitivity and specificity for Graves’ disease8, some patients show normal TRAb 
levels. In those cases, radionuclide scanning can be helpful for discriminating the disease from other causes of 
hyperthyroidism; however, the examination takes a relatively long time and is contraindicated for certain patients, 
such as pregnant women. Diagnosis of Graves’ ophthalmopathy is based on the examination of ophthalmologists 
combined with orbital imaging9. However, no simple diagnostic serum marker distinguishing ophthalmopathy 
among Graves’ disease has been developed yet.
Recently, studies on metabolomics are widely conducted to discover diagnostic biomarkers or indicators of 
drug responsiveness, or to elucidate underlying pathogenesis of diseases. The diagnosis of many autoimmune dis-
eases is delayed due to their obscure symptoms, and their pathogenesis remains to be elucidated10. Research stud-
ies on metabolomics using various biological specimens in autoimmune diseases have been actively conducted. 
Therefore, this study aimed to investigate novel biomarkers using metabolomics in Graves’ disease.
Here, non-targeted metabolite profiling was performed using GC-MS to characterize the Graves’ disease and 
to explore the potential biomarker for clinical application. GC-MS-based metabolite profiling is known for its 
reproducibility, robustness, and widely available public database11–14, which allows the technology to be most 
competent for exploratory or hypothesis-generating research14. Accordingly, the multivariate statistical modeling 
with primary metabolites suggested a putative biomarker panel unique to the disease, and the dysfunctional 
metabolic traits were mainly characterized by the hyperactivity of the central carbon/nitrogen metabolisms. 
Furthermore, the metabolic discrepancy was identified in the patients with GO compared to the ones without 
GO and the healthy control that may aid the mechanistic understanding of the underlying pathophysiology of 
this disease subtype.
Results
Clinical characteristics. The total study subjects were 79 patients with a mean age of 35.8 ± 10.4 years. 
Six out of the 32 healthy subjects (18.8%) were male; 6 (28.6%) and 7 (26.9%) of the 21 GD patients without 
GO and 26 GO patients, respectively (p = 0.656), and this sex ratio is similar to that of Graves’ disease. The 
mean TSH, free T4, and T3 levels of GD patients without GO and GO group were within normal range with-
out a statistical difference. The mean TRAb levels of both groups were not significantly different (6.32 ± 8.28vs. 
11.70 ± 13.87, p = 0.140); however, the mean TSI was higher in the GO group than in the GD patients without GO 
(289.0 ± 139.8 vs. 462.3 ± 171.2, p = 0.003). When evaluating the thyroid status of patients, 11 (52.4%) of the GD 
patients without GO and 12 (46.2%) of GO patients had euthyroid. Among GD without GO group and GO group, 
patient with subclinical hypothyroidism were 2 (9.5%) and 2 (7.7%), respectively. Six (28.6%) and 10 (38.5%) 
patients of each group had subclinical hyperthyroidism. The number of patients with overt hyperthyroidism was 
2 in each group. Nineteen (90.5%) patients of GD without GO group and 24 (92.3%) of GO group were taking 
antithyroid drugs. The proportion of patients with antithyroid drugs or levothyroxine for each group was not 
statistically different (Table 1). Among patients with GO, 11 patients took steroids, 3 patients received radiation 
therapy for treatment of ophthalmopathy before sample collection. However, no patients with GO was receiving 
those treatment at the time of sample collection.
Quality control of mass spectrometric analysis. Prior to data analysis, we evaluated the stability and 
reliability of the mass spectrometric analysis. To minimize the potential of a systematic error including analytical 
stability, extraction process, derivatization, and mass spectrometric analysis were performed on all samples in 
randomized order. In addition, the quality control (QC) mixture consisting of 30 representative metabolites was 
analyzed every ten samples. The data for the quality control is provided as a score plot (Supplementary Fig. S1A), 
a score control chart (PC1 and PC2) of the QC mixture analyzed by PCA, which presented the constant levels of 
the compounds throughout the analysis (Supplementary Fig. S1B)12.
Evaluation of confounder effects on blood metabolism. Prior to the data analysis, we inspected a del-
eterious effect, which originated from drug medication on the metabolome. Multivariate statistics, MANCOVA, 
and PCA were applied to interrogate global impact of the medication on the blood metabolome15,16. The treat-
ment duration with methimazole was analyzed as a covariate, which may indicate the level of the medication, 
thus differentially affecting metabolite abundances. The result showed methimazole was not significantly related 
to blood metabolite levels in Graves’ disease group (F = 2.881, p = 0.441). Score scatter plot by PCA confirmed 
that no cluster was identified by the different levels of methimazole examined (Supplementary Fig. S2). Steroid 
and statin administrations were examined as covariates. The results indicated that their effects on the integrative 
blood metabolome were not generally significant (steroid: F = 1.698, p = 0.553 and statin: F = 0.577, p = 0.806). 
Potential effects of decreased disease activity due to a broad spectrum of disease duration and therapy were 
further examined at the metabolome level within the GO group. Disease duration and therapy were not sig-
nificantly correlated with the disease metabolome (disease duration: F = 0.180, p = 0.973, steroid: F = 0.651, 
p = 0.773, MANCOVA). Univariate statistical analysis supported the results where only two metabolites were 
affected by the previous steroid treatment. In addition, the score scatter plots by PCA demonstrated the minimal 
effects of combinatorial interactions among disease severity classifications and therapy on the blood metabolome 
(Supplementary Fig. S3). Likewise, the metabolic profiles of orbital adipose/connective tissues presented very low 
level of variation, with 24% relative coefficient of variation (%CV).
Multivariate statistical analysis and biomarker discovery of Graves’ disease. Non-targeted pro-
filing focusing on primary metabolite was performed on a total of 79 plasma samples using GC-TOF MS. Binbase 
algorithm identified and semi-quantified 90 blood metabolites based on Fiehn library and NIST08 library17,18. 
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The compounds fairly covered various biochemical categories, such as carbohydrate, fatty acid, amino acid, and 
organic acid. The data can be downloaded from the website (https://lms2.kookmin.ac.kr:446/index.php?hCode=−
PAPER_LIST&publication_name=inter_paper). To examine whether integrative blood metabolite profiles can 
distinguish patients with Graves’ disease from the control group, we performed unsupervised multivariate statis-
tics, PCA, using the first two principal components. The score plot, however, did not show clustering of subjects 
between the disease group and control. Thus, orthogonal projection to latent structure-discriminant analysis 
(OPLS-DA), supervised multivariate statistics, was applied to obtain an overview of the metabolic uniqueness and 
potential biomarker. The OPLS-DA model performed with 7-fold cross validation showed the high levels of an 
explained variance (R2Y) of 0.812 and predictability (Q2Y) of 0.559 (Fig. 1A). To avoid overfitting, the model was 
validated with permutation test with 999 iterations that resulted in intercepts of R2 and Q2 with values of 0.555 
and −0.594, respectively (Fig. 1B).
Based on the model, biomarker candidates were prioritized by variable importance in project (VIP)19. 
Considering the potential applicability20, the number of the putative biomarkers was limited to 10 metabolites. 
The metabolites were glucose, pelargonic acid, fumaric acid, gluconic acid, glycerol, mannose, threose, pentade-
canoic acid, pyruvate, and 2-(4-hydroxyphenyl)ethanol. Following the re-composition of the metabolite panel, 
the performance as biomarker was assessed using the receiver operating characteristic (ROC) curve analysis. The 
area under ROC curves (AUC), sensitivity, and specificity were computed with the confidence intervals for the 
metabolite re-composite. The AUC of the biomarker panel was 0.931 for the disease against the healthy control 
with 0.787 of sensitivity and 0.875 of specificity (Fig. 2). The 95% confidence intervals (CIs) were computed using 
non-parametric re-sampling (500-time bootstrapping). In addition, ROC analysis was performed on a data set 
that was randomly selected and composed of 30% (26 subjects) of all subjects (79 subjects) as a validation set. This 
step was repeated three times (Supplementary Fig. S4).
A range of metabolic disturbance in primary metabolism by the disease. Next, we explored a 
potential linkage of the molecular biochemistry of the disease reflected in the blood metabolite. Thus, we inter-
rogated the compositional changes in metabolites. Including 10 metabolites that were selected as components of 
the potential biomarker panel, a total of 37 compounds were significantly different between the disease group and 
healthy controls (Table 2). Seventeen metabolites were significantly up-regulated, whereas 20 compounds were of 
lower abundance in the disease group. The most significant increase was found in pyruvate, alpha-ketoglutarate, 
uracil, fructose, proline, and glucose 6-phosphate. The dramatic down-regulation was observed in glucose, 
Parameters GD (n = 21) GO (n = 26) P value
Age, years 36.4 ± 10.4 39.5 ± 10.3 0.316
Male gender, n (%) 6 (28.6%) 7 (26.9%) 0.900
Disease duration, month 33.5 ± 32.3 39.4 ± 46.6 0.625
T3, ng/mL 1.04 ± 0.31 1.11 ± 0.37 0.474
Free T4, ng/dL 1.02 ± 0.19 1.13 ± 0.25 0.108
TSH, μIU/mL 2.13 ± 4.09 1.49 ± 3.56 0.570
TRAb, IU/L 6.32 ± 8.28 11.70 ± 13.87 0.140
TSI, % 289.0 ± 139.8 462.3 ± 171.2 0.003
Thyroid function status, n (%) 0.915
  Euthyroidism 11 (52.4%) 12 (46.2%)
  Subclinical hypothyroidism 2 (9.5%) 2 (7.7%)
  Subclinical hyperthyroidism 6 (28.6%) 10 (38.5%)
  Overt hyperthyroidism 2 (9.5%) 2 (7.7%)
Methimazole dose, mg 8.6 ± 5.1 11.8 ± 7.1 0.090
Antithyroid drug administration, n (%) 19 (90.5%) 24 (92.3%) 0.610
Levothyroxine dose, mcg 40.5 ± 47.1 52.9 ± 43.8 0.355
Levothyroixne administration, n (%) 11 (52.4%) 18 (69.2%) 0.237
CAS
  0 14 (53.8%)
  1 3 (11.5%)
  2 3 (11.5%)
  3 3 (11.5%)
  4 1 (3.8%)
Proptosis, mm 18.6 ± 2.6
NOSPECS 2.7 ± 1.6
Previous treatment for GO
  Glucocorticoid 11 (42.3%)
  Radiation therapy 3 (11.5%)
Table 1. Baseline characteristics of patients. Data are presented as mean ± SD or number (%). GD, Graves’ 
disease; GO, Graves’ ophthalmopathy; CAS, clinical activity score.
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mannose, gluconic acid lactone, and pentadecanoic acid. Pathway enrichment analysis proposed the most signif-
icant alteration in sugar metabolism, including galactose metabolism, starch metabolism, and pentose phosphate 
pathway (Supplementary Fig. S5). Others were glycerolipid and amino-sugar metabolism. A range of amino acid 
metabolisms was characterized by a high rank of pathway impact, which implies that the key metabolites in the 
Figure 1. Multivariate statistical model by OPLS-DA and model validation based on permutation test. (A) 
The score plot for the first two predictive component (t[1] and t0[1]) discriminates plasma metabolite profiles 
between healthy control and Graves’ disease groups. Red circle is T2 ellipse indicating 0.05 as significance level. 
(B) 999 times random permutation plot with 4 components on the datasets that corresponded to the two groups 
(healthy controls and GD). The vertical axis corresponds to R2 (green points) and Q2 (blue points) values, 
presenting the goodness of fit and predictability of the original model, respectively. The horizontal axis indicates 
the correlation coefficient between the original Y-variable and the permuted Y-variable. The test demonstrates 
the OPLS-DA model’s robustness by the criteria where the original values are plotted on the right and higher 
than those of the 999 permuted models.
Figure 2. (A) Receiver operating characteristic (ROC) analysis of multiple metabolite panels for discriminating 
the healthy control and Graves’ disease group. Score matrix (t[1]) is computed based on relative concentration 
of 10 metabolites by OPLS-DA and the single numerical variable is introduced for ROC analysis. The 10 
metabolites are glucose, pelargonic acid, 2-(4-hydroxyphenyl)ethanol, gluconic acid lactone, glycerol, 
pentadecanoic acid, mannose, threose, fumaric acid, and pyruvic acid. The value of the area under curve (AUC) 
is 0.93 (95% confidence interval: 0.862–0.969). Optimal cutoff is determined using the closest to top-left corner 
and the 95% confidence interval is calculated using 500 bootstrappings. (B) Box-and-whisker plot present the 
relative abundances of the variable (t[1] component) of healthy control (left) and GD (right).
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pathways were significantly altered (relative-betweenness centrality > 0.2). Next, we sought a potential linkage 
of the dysregulated metabolites with two clinical parameters that presented abnormality after medication, TRAb 
and TSI. Two-way OPLS (O2PLS) was applied to identify putative relation that resulted in clusters where distance 
and direction among variables indicated positive and negative correlations21. The association analysis identified 
the metabolites that were closely associated with TRAb whereas TSI showed comparably moderate relation to 
the metabolites (pq(corr) < 0.5) (Fig. 3). Most of the metabolites of the biomarker signature positively corre-
lated with TRAb level were the constituents of the biomarker panel (glucose, mannose glycerol, pelargonic acid, 
and pentadecanoic acid). In addition, the strong negative correlation was identified with pyruvate. Others were 
2-hydroxyhexanoic acid and 2-ketoisocaproic acid under negative association with TRAb.
Graves’ disease vs Control Graves’ disease vs Control
Metabolites p-value Fold change Metabolites p-value Fold changea
Pyruvate 2.09E-05 5.21 Stearic acid 4.02E-05 0.85
Alpha-ketoglutarate 1.37E-03 2.61 1,5-anhydroglucitol 4.46E-02 0.82
Uracil 1.46E-03 1.96 Malonic acid 3.58E-03 0.82
Fructose 3.30E-02 1.75 Salicylaldehyde 2.26E-04 0.80
Proline 6.28E-03 1.70 Hexonic acid 6.43E-03 0.79
Glucose-6-phosphate 3.56E-04 1.67 1-monopalmitin 2.57E-03 0.77
Oxoproline 4.30E-03 1.57 Threose 3.27E-07 0.77
Citramalic acid 1.03E-02 1.55 Xanthine 6.74E-03 0.75
Ornithine 2.42E-03 1.42 Uric acid 3.59E-02 0.75
Fumaric acid 4.33E-05 1.40 Glycerol 5.83E-08 0.71
Adenosine-5-monophosphate 1.11E-02 1.40 Galactonic acid 2.05E-05 0.69
Fructose-6-phosphate 2.18E-02 1.30 3-hydroxypyridine 1.06E-03 0.69
2-hydroxyhexanoic acid 3.41E-03 1.29 2-(4-hydroxyphenyl)ethanol 1.09E-07 0.67
Phenylalanine 8.82E-04 1.22 2-hydroxypyridine 3.46E-04 0.64
2-ketoisocaproic acid 2.73E-02 1.21 Pelargonic acid 1.43E-07 0.63
Beta-alanine 2.70E-02 1.17 Sorbitol 1.36E-06 0.63
Valine 3.77E-02 1.13 Pentadecanoic acid 4.32E-07 0.60
Gluconic acid lactone 1.50E-07 0.57
Mannose 6.14E-06 0.56
Glucose 1.55E-09 0.50
Table 2. The list of blood plasma metabolites that present the significant differences between Graves’ disease 
and the healthy control. aData expressed as fold to healthy control.
Figure 3. Overview of the relationship between known immune markers (TRAb and TSI) and predictive 
metabolites. (A) Variable mapping on loading scatter plot by two-way orthogonal projection to latent structures 
(O2PLS). Metabolite and known immune markers (TRAb and TSI) are assigned as X and Y variables, 
respectively. Loading of the markers and GC-TOF/MS datasets was combined to one vector. X-axis and Y-axis 
indicate the combined vectors, pq(corr) and poso(corr) based predictive components 1 and 2, respectively. 
The resultant loading plot is set to correlation scale. Distance among variables indicates the level of association. 
Variables in opposite direction from center present a negative relation. Only metabolite name of biomarker 
constituent is visualized. Pink and blue ovals indicate positively and negatively associated metabolites with 
TRAb.
www.nature.com/scientificreports/
6Scientific REPORTS |  (2018) 8:9262  | DOI:10.1038/s41598-018-27600-0
Unique metabolic dysregulation of Graves’ ophthalmopathy defined by blood and tissue 
metabolome. Graves’ ophthalmopathy (GO) is an autoimmune inflammatory disorder of the orbit and peri-
orbital tissues, characterized by upper eyelid retraction, lid lag, swelling, redness (erythema), conjunctivitis, and 
bulging eyes (exopthalmos)22. It occurs most commonly in individuals with Graves’ disease7. Since no blood bio-
marker that uniquely diagnoses Graves’ disease has been developed, we sought the unique features reflected in the 
patients’ blood metabolites with GO. The pair-wise comparison with the control group showed the GO-specific 
and GD-common metabolic signatures (Fig. 4). Most of the metabolites were commonly altered in both subtypes 
or only at different levels in GD. Exclusive differences in GO were found in proline and 1,5-anhydroglucitol. 
The direct comparison of the primary metabolites indicated the significant differences in 1,5-anhydroglucitol 
and ethanolamine GD and GO. The metabolite levels of GO were similar to those of GD, but some extension of 
specificity was identified with the relatively lower statistical criteria (p < 0.1) as summarized in Fig. 5. The meta-
bolic intermediates of purine metabolism were present at higher levels in GO (IMP, xanthine, and uric acid). In 
contrast, the over-production of amino acids and TCA cycle intermediates was characteristic for the GD patients.
Subsequently, we examined if the metabolites presenting GO specificity may aid in the development of a 
diagnostic parameter in combination with 10 pre-selected metabolite panels that showed the moderate levels of 
discrimination between the patients with GO and GD. Indeed, the re-constructed biomarker model based on 
the 12 metabolites significantly improved the discrimination power among the three groups (healthy controls, 
GO, and GD without GO). The model achieved AUC values that ranged from 0.845 to 0.935 in all diagnostic sets 
(Supplementary Fig. S6).
Lastly, we analyzed the metabolic profiles collected from the orbital adipose/connective tissues of the GO 
patients and compared them with the corresponding tissues of healthy controls. A total of 24 metabolites were sig-
nificantly different in the GO patients, in which 11 and 13 compounds were present at higher and lower contents, 
respectively, compared to the healthy control (Table 3). The up-regulated metabolites included proline, fumarate, 
and phenylalanine that were consistent with the expression pattern in blood metabolite analysis. The activated 
tissue metabolism was represented by amino acids, including asparagine, valine, allo-threonine, methionine, and 
glycine. Intermediates of nucleotide metabolism (adenine, guanosine, and inosine) showed the decreased levels 
in the tissue of GO patient that was accompanied by the reduction of ribose, glucose 6-phosphate, and fructose 
6-phosphate. As to the consistency, the decreased level in glycerol was compatible with the change in blood levels.
Discussion
To our knowledge, the current study is the first metabolomics investigation on GO particularly at both levels of 
blood plasma and orbital tissue. The interrogation first demonstrated that blood metabolic profiles were unique 
to GD, and biomarker cluster discriminated GD from healthy controls. The metabolome-wide multivariate cor-
relation analysis identified putative association of TRAb, a pathognomonic marker with the metabolites that were 
selected as the biomarker cluster. Consecutive examination on the blood plasma and orbital fibroblast tissue of 
the patients diagnosed as GO presented unique and consistent metabolic traits despite broad disease spectrum 
(therapies and disease severity).
Figure 4. Venn diagram of the metabolite list indicating the disease type-specific and -common types. Pink 
and yellow circles include the metabolites that are present at significantly different levels in GD with GO and 
GD without GO, respectively. The overlapping region includes common metabolites that pass through statistical 
criteria with same direction. Red indicates the metabolites with the significantly increased levels compared to 
the healthy control whereas blue presents the metabolite with significantly lower levels compared to the healthy 
control (p < 0.05).
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GD is an autoimmune disorder triggered by confluence of genetic and environmental factors. Genetic studies 
have identified genetic susceptibility associated with GD (e.g. thyroid stimulating hormone receptor (TSHR) gene 
and thyroglobulin (TG) gene)23,24. A recent study has revealed the mechanistic causality, in which microenviron-
mental cues (e.g. cytokine) modulated chromatic structure with a single-nucleotide polymorphism (SNP)25. Since 
some metabolic features signify phenotypic transition connecting genetic and environmental factors to converging 
endpoints of complicated disorders26, metabolomic investigation coupled with biomarker discovery in our study 
would provide integrative and extensive perspective for better understanding of disease mechanism and causality.
In this study, since the average thyroid hormone levels were within normal range, and most of patients were 
euthyroid or had mild thyroid function abnormalities, we pursued thyroid autoimmunity associated specific 
markers rather than thyroid hormone effect. First, we proposed a new biomarker cluster combined with 10 blood 
metabolites that can discriminate patients with Graves’ disease from the healthy controls. Interestingly, most of 
the metabolites of the biomarker panel showed the association with a known clinical determinant, TRAb and TSI. 
The associated metabolites were characterized by carbohydrate metabolism (glucose, mannose, threose, pyruvate, 
and fumarate) and fatty acid metabolism (pelargonic acid and pentadecanoic acid). Among them were glycerol, 
an intermediate of both metabolisms that reached the closest univariate statistical criteria between GO and GD 
(p = 0.28). The potential connectivity was further extended to the intermediates of central carbon metabolism 
(glucose-6 phosphate, α-ketoglutarate, and pyrophosphate), and nucleotide metabolism (uracil and adenosine-5 
monophosphate). Considering that the patients were under euthyroid condition (equivalent level of TSH to the 
healthy control) but pathological condition, the co-regulated alteration with TSI and TRAb may unveil additional 
pathological relatedness and new therapeutic approaches beyond TSH regulation.
The subsequent interrogation on the dysregulated metabolites including the biomarkers revealed the potential 
patho-biochemical linkages. Pathway enrichment analysis indicated overall dysregulation in carbohydrate and 
amino acid metabolisms. The activation of glycolysis27 was accompanied by the integrative activation of PPP28 
and glutaminolysis29. The alteration in the central carbon metabolism may be linked to the hyperactivity in energy 
metabolism and excessive ROS stress that has been reported in a range of pathogenic immune responses30–32. 
In addition, the increased level in succinate of TCA cycle (p-value 0.06) has been proposed to play a key role 
in innate immune signaling through enhancement of IL-1b production during inflammation33. The enhanced 
glutaminolysis was reflected in the increased level of α-ketoglutarate and also linked to the accumulation of 
Figure 5. Primary metabolic pathway representing distinctive metabolic dys-regulation among GO, GD, and 
healthy control. Pathway is manually re-organized for visual clarification and better explanatory overview on 
based on metabolites that are present at different concentrations and mappable into central carbon and nitrogen 
metabolism. Metabolite labeled with red color shows different levels of concentration both in GC and GO 
compared to healthy controls. Metabolite labeled with blue color presents exclusive difference in metabolites 
contents between GO and the healthy control whereas green color shows the significantly different abundance 
only in GD compared to healthy controls (p < 0.1). The relative concentrations are present as box-and-whisker 
plot indicating 1 × S.E. and 1.96 × S.E., respectively.
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intermediates in polyamine metabolism essential for T cell activation under GD. As identified in the pathway 
analysis, the alteration in the range of amino acid metabolisms was a characteristic consequence of the patho-
physiology. Excessive levels of leucine and valine may induce excitotoxicity on immune cells and result in the 
abnormal function of the immune profile34.
We further interrogated the unique metabolic dysfunction of Graves’ ophthalmopathy (GO), for which no spe-
cific blood biomarker has been developed among patients with Graves’ disease. Two metabolites showed signifi-
cant differences between the disease groups with or without GO: 1,5-anhydroglucitol and ethanolamine. Note that 
1,5-anhydroglucitol and ethanolamine conferred great improvement for discrimination power particularly between 
GO and the disease group without GO. In addition, we cross-checked the specificity of the biomarker panel against 
over 40 references (supplementary information file). Among the 12 metabolites proposed in this study, 4 compounds 
have been reported as the constituents of biomarker from multiple studies on multiple sclerosis (MS) from CSF 
samples. Less than two metabolites have been reported as biomarkers from other autoimmune diseases (rheumatoid 
arthritis, systemic lupus erythematosus, Behcet’s disease, neuromyelitis optica spectrum disorders, and coeliac dis-
ease), which implied the importance and uniqueness of multi-component biomarker panel as this study35.
Next, we sought the unique metabolic signature of the disease group with GO by analyzing orbital fibroblast 
tissue of patients with the corresponding tissue of healthy controls. Primarily, the tissue-specific metabolic dysreg-
ulation was remarked with the intermediates of nucleotide metabolism that was not identified in the blood metab-
olome. The abnormality in nucleotide metabolism may indicate the higher demands on RNA and DNA synthesis 
for proliferation under immune cell activation36. Likewise, cellular reprogramming of glycolytic pathway under 
this disease condition implied enhanced bioenergetics, which showed an opposite pattern to the one in the blood. 
The analysis also determined the coordinated changes between tissue and blood levels in proline, fumarate, and 
phenylalanine. The aromatic amino acid, phenylalanine contents are closely associated with immune activation and 
inflammation37. The result emphasized the significance of the parallel investigation on biofluid and tissue (organ).
There are some limitations of our study. The samples used in this study were from patients with relatively 
mild to moderate thyroid function abnormalities due to an avoidable medication for GO prior to surgeries38. The 
medication and a broad spectrum of disease duration may affect the clinical consequences (e.g. decreased disease 
activity and orbital decompression)39, and in turn the disease metabolome observed in blood and tissue although 
our multiple statistical evaluation proposed that the metabolomic dys-regulation was mainly affected by the dis-
ease category rather than by other confounding factors.
In summary, our study revealed the metabolome-wide dysregulation in GD by blood primary metabolite pro-
files that resulted in the characteristic metabolic linkage, putative biomarker panel discovery, and potential link-
age to causative association with important clinical marker, TRAb. In addition, we proposed unique metabolic 
features of GO that were further elaborated by the comparative analysis of orbital adipose/connective tissues, 
which may improve the pathological understanding of GO, and suggest potential therapeutic targets.
Graves’ op vs Control
Metabolites p-value Fold changea
Proline 1.50E-02 2.34
Malic acid 3.27E-02 2.27
Asparagine dehydrated 5.97E-04 2.24
Xanthosine 8.37E-03 2.22
Valine 1.32E-03 2.07
Fumaric acid 2.48E-02 2.05
Allothreonine 5.61E-03 2.05
Methionine 3.96E-03 1.94
Phenylalanine 6.80E-03 1.62
Asparagine 2.70E-03 1.52
Glycine 2.21E-02 1.40
Salicylaldehyde 4.66E-02 0.69
Glycerol 4.09E-02 0.69
Inositol-4-monophosphate 2.56E-02 0.64
Cholic acid 2.90E-02 0.53
Phosphoethanolamine 2.86E-02 0.48
Palmitic acid 1.82E-02 0.45
Ribose 1.93E-02 0.43
Adenine 1.63E-02 0.42
Fructose-6-phosphate 1.16E-02 0.34
Glucose-6-phosphate 3.71E-02 0.26
Guanosine 1.19E-02 0.25
Sucrose 4.00E-02 0.25
Inosine 3.69E-02 0.17
Table 3. The list of tissue metabolites that present the significant differences between Graves’ ophthalmopathy 
(GO) and the healthy control. aData expressed as fold to healthy control.
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Methods
Patient information and clinical manifestations. We evaluated patients with thyroid disease from 
October 2014 to January 2016 in Severance Hospital, Seoul, South Korea. Among these patients, patients with 
Graves’ disease diagnosed by previously known criteria, such as clinical symptoms of hyperthyroidism, in accord-
ance with thyroid function test, and positivity of TRAb were included40. The presence of Graves’ ophthalmopathy 
was diagnosed by ophthalmologists. A total of 48 patient blood samples were obtained, of which 26 patients have 
Graves’ ophthalmopathy (GO group) and 21 patients have Graves’ disease without Graves’ ophthalmopathy (GD 
group). Blood samples from 32 healthy controls without clinical evidence of Graves’ disease were also obtained. 
We collected and reviewed demographic and clinical data, including gender, age, clinical symptoms, thyroid func-
tion tests (TFT), thyroid autoantibodies, and thyroid medication history. The severity of ocular manifestation was 
assessed using clinical activity scores (CAS) of EUGOGO Classification41, the modified NOSPECS42, and exoph-
thalmometry at the time of blood sampling. This study was approved by and all the method were carried out in 
accordance with the Institutional Review Board of the Yonsei University College of Medicine (4-2014-0520). All 
of the patients provided informed consent.
Thyroid function and antithyroid antibody tests. For thyroid function evaluation, we measured 
serum concentrations of TSH (normal range, 0.35–4.94 IU/mL), free T4 (normal range, 0.70–1.48 ng/dL), and 
T3 (normal range, 0.58–1.59 ng/mL) using a microparticle chemiluminescence immunoassay (Abbott Ireland 
Diagnostics Division, Longford, Ireland). Thyroid status of patients was defined as follows40,43: euthyroid included 
TSH level within the normal range; hypothyroid patients had a low free T4 concentration and elevated TSH levels, 
whereas patients with subclinical hypothyroidism had elevated TSH with normal free T4; hyperthyroid patients 
had elevated free T4 with suppressed thyrotropin; and subclinical hyperthyroid was defined as a low thyrotropin 
with normal free thyroxine.
Thyrotropin receptor antibodies were evaluated by two different methods: M22-TRAb (TRAb) was checked 
using a third-generation TBII electrochemiluminescence immunoassay (Elecsys/Cobas; Roche Diagnostics, 
Mannheim, Germany), and Mc4-TSAb (thyroid-stimulating immunoglobulin, TSI) was measured using the 
Thyretain™ TSI reporter Bio Assay (Diagnostic Hybrids, Inc., Athens, OH, USA). The positivity of antibody 
tests was defined as TRAb levels higher than 1.75 IU/L or Mc4-TSAb levels higher than the standard value of the 
sample ratio of 140%.
Sample preparation. All individuals fasted for 8 h prior to the blood collection. The blood samples were 
collected in BD Vacutainer tubes containing the chelating agent K2 ethylenediaminetetraacetic acid (EDTA), and 
centrifuged at 2,000 g for 10 min at room temperature. The plasma samples were separated, aliquoted, and stored 
at −80 °C. Once all samples were collected, the tubes were marked with a unique number to blind them.
Tissue collection. Orbital adipose/connective tissues were obtained from surgical waste of 5 patients 
with GO during orbital decompression surgery for severe proptosis (3 men and 2 women; mean age of 53.6 
years) (Supplementary Table S1). We also collected normal control fat/connective tissues from 5 individu-
als without history or clinical evidence of autoimmune thyroid disease or GO during eyelid or orbital surgery 
for non-inflammatory conditions (3 men and 2 women; mean age of 52.8 years). All 5 patients with GO had 
well-controlled thyroid function at the time of surgery with or without antithyroid medication. None of the patients 
with GO was treated with radiation before the orbital surgery. Clinical activity scores of GO patients were less than 4. 
This study was approved by and all the method were carried out in accordance with the Institutional Review Board 
of the Yonsei University College of Medicine (4-2014-0292). All of the patients provided informed consent.
Blood plasma metabolite extraction. The extraction process, derivatization, and mass spectrometric 
analysis were performed for all samples in randomized order. The extraction procedure, which was conducted 
for primary metabolite profiling, was as follows: an aliquot of serum samples (50 µL) was extracted with 750 µL 
of tertiary organic solvent (methanol:isopropanol:water, 3:3:2, v/v/v). The mixtures were shortly vortexed, soni-
cated for 5 min, and centrifuged for 5 min (13,200 rpm at 4 °C). The supernatant (700 µL) was transferred to a new 
1.5-mL tube and dried in a speed vacuum concentrator (SCANVAC, Korea). Dried residual was stored at −80 °C 
until mass spectrometric analysis.
Tissue metabolite extraction. The obtained tissue was freeze-dried until analysis. The lyophilized tissue 
was ground using a single 5 mm i.d. steel ball, followed by the addition of 0.75 mL extraction solvent of metha-
nol:isopropanol:water (3∶3:2) and was vortexed. After a 5-min centrifugation at 16,100 g, 0.70 mL of extracts was 
collected and concentrated to dryness for further analysis44.
Chemical derivatization. The dried metabolites underwent methoxyamination with 5 µL of 40 mg/mL 
methoxyamine hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) in pyridine (Thermo, USA) (90 min at 
30 °C). The derivative was then reacted with 45 µL of N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA + 
1% TMCS; Thermo, USA) (1 h at 200 rpm and at 37 °C) for trimethylsilylation process. A mixture (2 µL) consist-
ing of 13 fatty acid methyl esters (FAME) was spiked as a retention index marker, which included C8, C9, C10, 
C12, C14, C16, C18, C20, C22, C24, C26, C28, and C3045.
GC-TOF MS analysis. The injection of derivatized metabolite was controlled by an Agilent 7693 ALS 
(Agilent Technologies, Wilmington, DE, USA) in splitless mode. Gas chromatography and mass spectrome-
try were conducted using an Agilent 7890B gas chromatograph (Agilent Technologies) and Leco Pegasus HT 
time of flight mass spectrometer (LECO, St. Joseph, MI, USA). Gas oven temperature was set to 50 °C for 1 min, 
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increment at 20 °C/min to 330 °C, and hold for 5 min. Transfer line and ion source temperatures were set to 280 °C 
and 250 °C, respectively. Mass spectra were acquired ranging from 85 to 500 m/z at a scan rate of 17 spectra/sand 
a detector voltage of 1650 V20.
Data pre-processing was done by ChromaTOF software (version 4.5), which included apex mass values, the 
entire spectrum, signal-to-noise ratio, peak purity, and retention time. Generic text file (.txt) and netCDF file 
were produced based on raw file (.peg) for peak identification and semi-quantification. The post-process was 
performed using Binbase algorithm consisting of chromatogram validation, primary RI detection, and validation 
of unique mass17,46.
Quantitative value was computed using the peak height of the single unique mass. Missing values that did 
not pass the primary criteria were imputed by post-matching and replacement using raw data as previously 
described12,47. To check the analytical stability, a mixture of 30 pure reference compounds were analyzed every 
10 samples48.
Statistical analysis. Processed data from both GC- and LC-MS analyses were normalized by the sum of 
identified peaks or selected features of each chromatogram, respectively. Univariate statistical analyses were con-
ducted using the Statistica software version 7.1 (StatSoft, Tulsa, OK, USA). The multivariate statistical analysis 
(OPSL-DA and O2PLS) and Receiver Operating Characteristic (ROC) analysis were performed using SIMCA 
14 (Umetrics AB, Umea, Sweden). OPLS-DA was performed using 7-fold cross-validation and permutation 
test (N = 100). For validation of ROC analysis, the 95% confidence interval using bootstrapping was done by 
Biomarker analysis module implemented in MetaboAnalyst 3.036,49.
Pathway enrichment analysis was performed using MetaboAnalyst 3.0. Pathway analysis with metabolite 
expression data was evaluated for statistical significance using the hypergeometric test and pathway topology was 
analyzed based on the relative-betweenness centrality. Multivariate analysis of covariance (MANCOVA) based 
on the Pillai-Bartlett statistics was conducted15 using IMB SPSS Statistics (version 22.0, IBM Corp., Armonk, 
N.Y., USA).
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